Navigation Links
IKARIA(R) to In-License BioLineRx's BL-1040
Date:7/6/2009

CLINTON, N.J. and JERUSALEM, July 6 /PRNewswire/ -- Ikaria Holdings, Inc. and BioLineRx Ltd. (TASE: BLRX) today announced that Ikaria has entered into an agreement to obtain a worldwide exclusive license to BioLineRx's BL-1040, a potential breakthrough treatment for preventing pathological cardiac remodeling following acute myocardial infarction (AMI).

BL-1040, currently in a phase I/II clinical trial, is administered via the coronary artery during standard catheterization and flows into the damaged heart muscle, where it forms a protective "scaffold" that enhances the mechanical strength of the heart muscle during recovery and repair. BL-1040 is the first program to graduate from the BIJ (BioLine Innovations Jerusalem) incubator subsidized by the Israeli Office of the Chief Scientist.

Under the terms of the agreement, BioLineRx will receive upfront and milestone payments. BioLineRx will also receive royalties on annual net sales. Ikaria will be responsible for completing clinical development and commercialization efforts. The deal is contingent upon receipt of the approval of the Israeli Office of the Chief Scientist.

"The acquisition of the rights to BL-1040 reinforces our commitment to deliver novel treatments to critically ill patients around the world," commented Daniel Tasse, President and CEO of Ikaria. "Millions of patients suffer from MI each year, and BL-1040 represents the potential of an exciting solution to the problem of ventricular remodeling following AMI, for which the unmet need remains very high."

"This agreement is consistent with our business model of developing early-stage programs through human Proof of Concept trials and ultimately partnering with a global therapeutics company that has the expertise and resources to complete development and commercialization," said Morris C. Laster, M.D., CEO of BioLineRx. "Ikaria's deep and singular focus on therapies for patients
'/>"/>

SOURCE Ikaria Holdings Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Ikaria(R) to Present at 27th Annual JPMorgan Healthcare Conference
2. Ikaria(R) Strengthens Commercial Operations and Human Resources Leadership
3. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... May 26, 2015 The University ... the Max Planck Society establishing the Max ... The center will link two of the world's foremost ... be only the third Max Planck Centre in North ... society for optics and photonics, was with university ...
(Date:5/26/2015)... WORMS, GERMANY – May 26, 2015 ... announces that its manufacturing facility in Worms, Germany ... EXCiPACT™, an independent organization that certifies manufacturers, suppliers, ... All three Grace facilities that produce its SYLOID® ... have now received GMP certification, following the Curtis ...
(Date:5/26/2015)... REDWOOD CITY , Kalifornien und HILDEN, ... QIAGEN Clinical Insight ... Interpretation von Genvarianten und die Erstellung dazugehöriger ... und ESHG     QIAGEN N.V. ... QIA) gab heute die Markteinführung von QIAGEN ...
(Date:5/26/2015)... RICHMOND, Calif. , May 26, 2015  Sangamo BioSciences, ... Lanphier , Sangamo,s president and CEO, will provide an update ... programs and an overview of the company,s business strategy at ... 2015 Global Healthcare Conference. The conference is being held in ... presentation will be webcast live and may be accessed via ...
Breaking Biology Technology:Third Max Planck Centre in North America Inaugurated at University of Ottawa 2Third Max Planck Centre in North America Inaugurated at University of Ottawa 3CORRECTION: Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 2QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 3QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 4QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 5QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 6Sangamo BioSciences Announces Presentation At The Jefferies 2015 Global Healthcare Conference 2
... 16 /PRNewswire-Asia-FirstCall/ -- A-Power Energy,Generation Systems, Ltd. (Nasdaq: ... of distributed power generation ("DG") systems in China and ... signed a,contract with Sanmenxia New Energy Bio-Electricity Co., Ltd. ... Province of,China. , Pursuant to ...
... SYDNEY, June 16 /PRNewswire-Asia/ -- Pharmaceutical company ... announce that additional results of its,recently completed international Phase III ... at the 2009 European Cystic Fibrosis,Conference in Brest, France. , ... conference on Friday 12 June by Dr Diana,Bilton of the ...
... Sharoky, M.D. to Assume the Role of Chairman of the ... Insmed Inc. (Nasdaq: INSM ), a biopharmaceutical company, ... President, Chief Executive Officer and Chairman of the Board of ... Allan has served as Insmed,s President, Chief Executive Officer and ...
Cached Biology Technology:A-Power Energy Generation Systems Ltd. Signs a Biomass-Based DG Contract with Sanmenxia New Energy Bio-Electricity Co., Ltd. 2A-Power Energy Generation Systems Ltd. Signs a Biomass-Based DG Contract with Sanmenxia New Energy Bio-Electricity Co., Ltd. 3Phase 3 Cystic Fibrosis Trial Results Presented at European Conference 2Phase 3 Cystic Fibrosis Trial Results Presented at European Conference 3Phase 3 Cystic Fibrosis Trial Results Presented at European Conference 4Insmed CEO Resigns Due to Health Concerns 2Insmed CEO Resigns Due to Health Concerns 3
(Date:4/20/2015)... 2015 The announcement comes as ... Records Management (GRM), Ireland,s foremost records ... Having built up an impressive track record of clients within ... within the records management sector in Dubai ... GCC staffbase and employ a further eight staff members at ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/13/2015)... 2015 According to a ... Market Forecast & Opportunities, 2020", the global biometrics market ... 14% till 2020. The biometrics market is garnering ... and review of biometric management systems. The constant ... with greater efficiency, are resulting in increasing installation ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... E supplements may blunt the improvement of muscular endurance ... new study published today [3 February] in The Journal ... widely used, understanding if they interfere with cellular and physiological ... health purposes as well as to athletes., Dr Gran Paulsen, ...
... Immune cells undergo ,spontaneous, changes on a daily basis ... diligent surveillance of our immune system, Melbourne scientists have ... Eliza Hall Institute found that the immune system was ... their early stages, before they developed into B-cell lymphomas ...
... In many people with autism and other neurodevelopmental disorders, ... other very well. Scientists have now identified, for the ... connectivity can come about. In a study published online ... European Molecular Biology Laboratory (EMBL) in Monterotondo, Italy, and ...
Cached Biology News:Vitamin C and E supplements hampers endurance training 2Red alert: Body kills 'spontaneous' blood cancers on a daily basis 2Making your brain social 2